[
  {
    "ts": null,
    "headline": "PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology",
    "summary": "PAVmed Inc. (Nasdaq: PAVM) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has executed a non-binding letter of intent with Duke University to license, through a newly-formed subsidiary, Duke's technology to identify and facilitate treatment of advanced esophageal precancer (dysplasia) during upper endoscopy. This technology—a multi-modality probe combining an",
    "url": "https://finnhub.io/api/news?id=17804b17bbc9b70c30f083f814e3bb7c88a26834c5b518d758839200686e7ef2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756209660,
      "headline": "PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology",
      "id": 136524586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DUK",
      "source": "Yahoo",
      "summary": "PAVmed Inc. (Nasdaq: PAVM) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has executed a non-binding letter of intent with Duke University to license, through a newly-formed subsidiary, Duke's technology to identify and facilitate treatment of advanced esophageal precancer (dysplasia) during upper endoscopy. This technology—a multi-modality probe combining an",
      "url": "https://finnhub.io/api/news?id=17804b17bbc9b70c30f083f814e3bb7c88a26834c5b518d758839200686e7ef2"
    }
  }
]